China Universal Asset Management Company’s Stoke Therapeutics STOK Stock Holding History

China Universal Asset Management Company’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$331K	Sell	10,112 -5,024	-33%	-$161K	0.02%	307
2026 Q1	$493K	Buy	15,136 +2,229	+17%	+$73.1K	0.04%	262
2025 Q4	$410K	Buy	12,907 +3,302	+34%	+$99.3K	0.03%	278
2025 Q3	$226K	Sell	9,605 -1,361	-12%	-$23.3K	0.02%	324
2025 Q2	$124K	Buy	10,966 +342	+3%	+$3.25K	0.01%	345
2025 Q1	$70.7K	Sell	10,624 -607	-5%	-$5.66K	0.01%	389
2024 Q4	$124K	Buy	+11,231	New	+$138K	0.01%	370
2023 Q4	–	Sell	-1,132	Closed	-$4.46K	–	478
2023 Q3	$4.46K	Buy	1,132 +553	+96%	+$3.64K	﹤0.01%	398
2023 Q2	$6.16K	Buy	579 +44	+8%	+$468	﹤0.01%	352
2023 Q1	$4.46K	Buy	535 +134	+33%	+$1.21K	﹤0.01%	377
2022 Q4	$3.7K	Buy	401 +32	+9%	+$333	﹤0.01%	333
2022 Q3	$5K	Buy	+369	New	+$5.88K	﹤0.01%	277

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

China Universal Asset Management Company's STOK Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Stoke Therapeutics (STOK) stake by 33% in Q2 2026, selling an estimated $161K and leaving 10,112 shares worth $331K. The position accounts for 0.02% of the portfolio, ranked #307.

China Universal Asset Management Company first reported a position in STOK in Q3 2022 and has held it in 12 quarters since. The position peaked at $493K in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

China Universal Asset Management Company held 10,112 shares of Stoke Therapeutics worth $331K as of Q2 2026.
China Universal Asset Management Company sold 5,024 Stoke Therapeutics shares in Q2 2026, an estimated $161K.
Stoke Therapeutics made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #307 holding.
China Universal Asset Management Company first reported a position in Stoke Therapeutics in Q3 2022 and has held it in 12 quarters since.
China Universal Asset Management Company's Stoke Therapeutics position peaked at $493K in Q1 2026.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.